Trastuzumab Biosimilar Antibody (Anti-HER2) from ProteoGenix; catalogue PX-TA1005; research use only.
Know who made it. See the evidence. Buy through one marketplace.
The trastuzumab biosimilar antibody is a recombinant anti-HER2 monoclonal antibody designed for research applications. HER2 (Human Epidermal Growth Factor Receptor 2) is a transmembrane receptor involved in cell proliferation and signaling pathways, making it a widely studied target in oncology and cell biology.
This trastuzumab biosimilar enables researchers to investigate HER2-mediated signaling, receptor binding, and antibody interactions in controlled experimental settings. It is suitable for laboratories working on antibody characterization, cell-based assays, and oncology-related research.
HER2 belongs to the epidermal growth factor receptor (EGFR) family and plays a key role in regulating cell growth and differentiation. Overexpression of HER2 has been extensively studied in cancer biology, making it an important target in research involving receptor signaling and antibody-based mechanisms.
Trastuzumab antibodies are commonly used in experimental studies to evaluate:
The trastuzumab antibody is suitable for a wide range of research applications, including:
Related Services
Researchers working with therapeutic antibodies and biosimilars may benefit from ProteoGenix expertise in:
Related Therapeutic Antibodies
ProteoGenix offers trastuzumab biosimilar antibodies at competitive market prices, allowing research laboratories to access high-quality reagents while optimizing project budgets.
Our biosimilar antibodies are produced under controlled conditions to ensure consistent quality, reproducibility, and cost-effective use in research applications.
ProteoGenix catalogue number PX-TA1005. For research use only.
Target: Trastuzumab Biosimilar; Clonality: Monoclonal Antibody; Expression system: Mammalian cells; Purity: >85%; Molecular weight: 145kDa; Buffer: PBS pH7.5; Applications: WB, ELISA.
Available configurations: 50ug, 100ug, 1mg, 10mg, 25mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Trastuzumab Biosimilar |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
